Cretostimogene PIVOT-006 phase 3 bladder cancer results infographic

Cretostimogene, CG Oncology’s bladder-instilled oncolytic immunotherapy, cut the risk of tumor recurrence by 68% versus surveillance in the phase 3 PIVOT-006 trial, the company reported on November 16, 2026. The study enrolled 367 patients with intermediate-risk and small high-grade Ta non-muscle invasive bladder cancer (NMIBC) across about 90 US and Canadian sites, a group for which no FDA-approved post-surgery treatment exists. Shares of CG Oncology (Nasdaq: CGON) jumped more than 30% before the market opened, according to Reuters.

Key takeaways on cretostimogene

  • PIVOT-006 met its primary endpoint: hazard ratio for recurrence 0.32 (95% CI 0.23 to 0.45; p<0.0001), a 68% risk reduction.
  • Median follow-up was 17 months at the October 26, 2026 data cutoff.
  • No grade 3 or higher treatment-related side effects and no discontinuations due to treatment were reported.
  • CG Oncology plans a BLA for this population in the second quarter of 2027, after a broadened BCG-unresponsive filing due before the end of March 2027.
  • Full data are scheduled as a late-breaking talk at the Society of Urologic Oncology meeting on December 2, 2026.

The problem PIVOT-006 set out to solve

Most bladder cancers are found while still confined to the inner lining of the bladder. Surgeons remove them through a scope, a procedure called transurethral resection of bladder tumor (TURBT). The trouble is what comes next: intermediate-risk tumors return often, and each recurrence means another cystoscopy, another resection and, for many patients, years of anxiety and repeat anesthesia. CG Oncology estimates about 50,000 patients a year fall into the intermediate-risk group it studied.

For these patients, doctors can choose single-dose chemotherapy in the bladder or courses of BCG, a tuberculosis-derived vaccine that has been the backbone of bladder cancer immunotherapy for decades and has faced repeated global supply shortages. Neither option is FDA-approved specifically as adjuvant therapy for this group, and many patients are simply watched. PIVOT-006 compared cretostimogene with that watchful approach after complete tumor removal.

Inside the PIVOT-006 numbers

MeasureResult
Patients enrolled367
SitesAbout 90 (US and Canada)
ComparisonAdjuvant intravesical cretostimogene vs surveillance after TURBT
Hazard ratio for recurrence0.32 (95% CI 0.23 to 0.45)
Recurrence risk reduction68%
Median follow-up17 months
Grade 3+ treatment-related adverse eventsNone reported
Source: CG Oncology topline announcement, November 16, 2026.

The upper end of the confidence interval, 0.45, still implies at least a 55% reduction in recurrence risk by our calculation, which suggests the effect is not a statistical fluke. Eligible tumors included recurrent low-grade Ta disease within a year, solitary low-grade Ta tumors larger than 3 cm, multifocal low-grade Ta, solitary high-grade Ta tumors of 3 cm or less, and low-grade T1 disease. Chief executive Arthur Kuan called the results “a defining milestone” for the company.

How an oncolytic virus treats bladder cancer

Cretostimogene grenadenorepvec is a modified adenovirus delivered through a catheter directly into the bladder. It is engineered to replicate preferentially in cancer cells, bursting them open, and to carry the gene for GM-CSF, an immune signal that recruits the body’s own defenses to the area. The local delivery keeps exposure in the bladder, which helps explain the mild side-effect profile reported so far. This dual action, direct killing plus immune activation, is what places it in the immunotherapy category alongside BCG and newer agents such as ImmunityBio’s Anktiva, covered in our report on the Anktiva FDA approval for papillary bladder cancer.

Limits of a topline readout

Topline press releases leave gaps. CG Oncology has not yet published recurrence-free survival rates at fixed time points, the randomization ratio, or detailed results for each tumor subgroup, and the comparator was surveillance rather than BCG or chemotherapy. Seventeen months is also a relatively short follow-up for a disease that can recur years later. Doctors will want to see whether the benefit holds for high-grade tumors, how many instillations patients needed, and how often progression to muscle-invasive disease occurred. Those answers should come at the SUO podium presentation and a later journal publication.

Surgical innovation is moving in parallel; the Virtuoso robotic system recently won FDA De Novo authorization for one-piece bladder tumor removal, which could improve the resections that precede adjuvant therapy.

Regulatory timeline and market context

Cretostimogene already holds FDA Fast Track and Breakthrough Therapy designations in BCG-unresponsive NMIBC, supported by the phase 3 BOND-003 study, whose carcinoma in situ cohort was published in The Lancet Oncology in July 2026. CG Oncology now plans to widen that first BLA to include high-grade papillary-only disease, completing it before the end of March 2027, followed by a second BLA for the PIVOT-006 population in the second quarter of 2027. The company says BLA-enabling manufacturing for both is complete.

The commercial stakes sit within a fast-growing field. Acumen Research and Consulting projected the global cancer immunotherapy market to grow at about 10.6% a year from 2019 to 2026, reaching around USD 115.4 billion by 2026, with North America the largest region and Asia-Pacific, including India, the fastest growing. The report was last updated in January 2020, so these figures are dated and indicative only.

Frequently asked questions

What is cretostimogene grenadenorepvec?

It is an investigational oncolytic immunotherapy, a modified adenovirus placed directly into the bladder that infects and kills cancer cells while stimulating an immune response. It is not yet approved anywhere.

What did the PIVOT-006 trial show?

Among 367 patients with intermediate-risk or small high-grade Ta NMIBC, cretostimogene after surgery reduced the risk of recurrence by 68% compared with surveillance, with no grade 3 or higher treatment-related side effects.

When could cretostimogene be approved?

CG Oncology plans to complete its BCG-unresponsive filing before the end of March 2027 and file for intermediate-risk disease in Q2 2027. Approval timing depends on FDA review.

Is it an alternative to BCG?

PIVOT-006 compared it with surveillance, not BCG, so no head-to-head conclusion is possible yet. Treatment choices should be made with a urologist.

Sources: CG Oncology PIVOT-006 announcement; Reuters market report, November 16, 2026. Market data: Acumen Research and Consulting. More in Clinical Trials. This article is not medical or investment advice. Last updated November 17, 2026.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

Leave a Reply

Your email address will not be published. Required fields are marked *